Marios Georgios Bantidos

Mr. Marios Georgios Bantidos

Medicine, Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CKChristos Kofos
Christos Kofos
APAndreas S Papazoglou
Andreas S Papazoglou
BFBarbara Fyntanidou
Barbara Fyntanidou
ASAthanasios Samaras
Athanasios Samaras
PSPanagiotis Stachteas
Panagiotis Stachteas
EKEfstratios Karagiannidis
Efstratios Karagiannidis
Background: Novel and accessible biomarkers may add to the existing risk stratification schemes in patients with acute coronary syndrome (ACS). The platelet-to-lymphocyte ratio (PLR) and glucose-to-lymphocyte ratio (GLR) have emerged as potential indicators of systemic inflammation and metabolic stress, both of which are pivotal in ACS pathophysiology. The aim of this study was to investigate the prognostic significance of the PLR and GLR in patients with ACS. Methods: We performed a retrospective cohort study of patients hospitalized with ACS between 2017 and 2023 at Hippokration Hospital of Thessaloniki, Greece. PLR and GLR were calculated from admission blood samples. The primary endpoint was all-cause mortality. Logistic and Cox regression models were used to investigate the associations of PLR and GLR with all-cause mortality. Receiver operating characteristic (ROC) analysis, Kaplan–Meier survival curves, and restricted cubic spline (RCS) modeling were also applied. Results: In total, 853 patients (median age: 65 years, 72.3% males) were included. Higher PLR and GLR were independently associated with increased risk of long-term mortality [adjusted Odds Ratio (aOR) for PLR: 1.007, 95% CI: 1.005–1.008; and for GLR: aOR = 1.006, 95% CI: 1.003–1.008]. The optimal cut-off values were 191.92 for PLR and 66.80 for GLR. Kaplan–Meier and Cox regression analyses confirmed significantly reduced survival in patients with GLR and PLR values exceeding these thresholds. RCS analysis revealed non-linear relationships, with mortality risk rising sharply at higher levels of both markers. PLR showed superior prognostic performance (AUC: 0.673, 95% CI: 0.614–0.723) compared to GLR (AUC: 0.602, 95% CI: 0.551–0.653). Conclusions: While PLR demonstrated greater predictive accuracy, both PLR and GLR were consistently associated with mortality and may provide complementary prognostic information. Incorporating those ratios into routine clinical assessment may improve risk stratification, particularly in resource-limited settings or for patients without traditional risk factors.

13 September 2025 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Open access
Marios Georgios BantidosMarios Georgios Bantidos
Marios Georgios Bantidos
NSNikolaos Stalikas
Nikolaos Stalikas
BFBarbara Fyntanidou
Barbara Fyntanidou
ISIoannis Skalidis
Ioannis Skalidis
AAAlexandra Arvanitaki
Alexandra Arvanitaki
EKEfstratios Karagiannidis
Efstratios Karagiannidis
Stress-Induced Hyperglycemia (SIH) represents a transient increase in blood glucose levels triggered by acute physiological stress, frequently observed in patients with Acute Coronary Syndrome (ACS). It is linked to adverse outcomes, including higher mortality and an increased risk of Major Adverse Cardiac and Cerebrovascular Events (MACCE). Despite this, SIH remains inadequately defined and underappreciated in clinical risk assessment and patient management. This narrative review delves into the mechanistic underpinnings of SIH in ACS (neuroendocrine, metabolic and inflammatory pathways). Evidence on current SIH markers [including the Stress-Hyperglycemia Ratio (SHR), Admission Blood Glucose, Glycemic Gap, and Glycemic Variability] was identified through searches of PubMed/MEDLINE for English-language human studies published between January 2017 and May 2025 (certain seminal earlier studies were also retained), with a focus on key subpopulations (diabetes, non-diabetes, and MINOCA). Particular emphasis is placed on SHR as a ratio of acute to chronic hyperglycemia with expanding prognostic applications. SIH is a multifaceted phenomenon, superiorly reflected by dynamic indices like SHR rather than traditional measures. Further research into the mechanisms linking SIH with adverse outcomes could lay the groundwork for interventional trials, ultimately reshaping ACS patient risk-stratification and management.

19 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PSPanagiotis Stachteas
Panagiotis Stachteas
Marios Georgios BantidosMarios Georgios Bantidos
Marios Georgios Bantidos
NPNikolaos Papoutsidakis
Nikolaos Papoutsidakis
ANAthina Nasoufidou
Athina Nasoufidou
PKPaschalis Karakasis
Paschalis Karakasis
Nikolaos FragakisNikolaos Fragakis
Nikolaos Fragakis
Atrial fibrillation (AF) is the most common sustained arrhythmia and a growing global health burden, yet conventional monitoring with Holter devices, event recorders and implantable loop recorders often fails to adequately capture recurrence. Rapid advances in digital health, wearable biosensors and artificial intelligence (AI) have transformed consumer smartwatches and wearables into potential clinical tools capable of continuous, real-world rhythm surveillance. This narrative review synthesizes contemporary evidence on smartwatch-based AF monitoring, spanning core technologies—photoplethysmography, single-lead electrocardiography and AI fusion algorithms—and validation studies across post-ablation follow-up. Compared with traditional modalities, smartwatch-based AF monitoring demonstrates improved detection of AF recurrence, enhanced characterization of AF burden, symptom–rhythm correlation, and greater patient engagement. At the same time, key limitations are critically examined, including motion artifacts, false-positive alerts, short recording windows, adherence dependence, digital literacy and access gaps, as well as unresolved issues around regulation, interoperability and data privacy. By integrating engineering advances with guideline-directed care pathways, smartwatch-based AF monitoring holds promise to complement, rather than immediately replace, established diagnostic tools and to enable more proactive, individualized AF management. Future work must focus on robust clinical validation, equitable implementation and clear regulatory frameworks to safely scale these technologies.

Verified
Journal Article
Open access
PDF file
ANAthina Nasoufidou
Athina Nasoufidou
Marios Georgios BantidosMarios Georgios Bantidos
Marios Georgios Bantidos
BFBarbara Fyntanidou
Barbara Fyntanidou
CKChristos Kofos
Christos Kofos
PSPanagiotis Stachteas
Panagiotis Stachteas
EKEfstratios Karagiannidis
Efstratios Karagiannidis
Ischemic heart disease remains the leading cause of death despite substantial advances in diagnosis, revascularization therapies, and risk-factor control. Beta-adrenergic receptor blockers (Beta-Blockers, BBs), long used to control heart rate, blood pressure, and reduce arrhythmic risk, may also confer cardioprotection through mechanisms beyond hemodynamic unloading. This review integrates an extensive range of preclinical, translational, and clinical studies to present a comprehensive overview of the cardioprotective effects of BBs in the context of myocardial ischemia and reperfusion injury. Mechanistic domains include modulation of redox homeostasis, attenuation of inflammation and neutrophil activation, preservation of mitochondrial integrity and anti-apoptotic signaling, improvement of endothelial function, and stabilization of calcium handling. Third-generation compounds, carvedilol and nebivolol, demonstrate additional antioxidant and vasodilatory benefits compared with first- and second-generation agents; however, no consistent class-wide effect exists across most pathways. The evidence base remains fragmented, often derived from agent- or context-specific studies in heterogeneous populations, with uncertainty surrounding optimal timing of intervention. By bridging mechanistic understanding with clinical outcomes, this review highlights the importance of standardized assessment of BB effects, the development of personalized treatment approaches, and the pursuit of future research to address ongoing translational gaps.

25 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CKChristos Kofos
Christos Kofos
PSPanagiotis Stachteas
Panagiotis Stachteas
BFBarbara Fyntanidou
Barbara Fyntanidou
APAndreas S Papazoglou
Andreas S Papazoglou
ASAthanasios Samaras
Athanasios Samaras
EKEfstratios Karagiannidis
Efstratios Karagiannidis
Background: The platelet-to-hemoglobin ratio (PHR) has emerged as a potential prognostic marker in various cardiovascular contexts, but its role in acute coronary syndrome (ACS), particularly among patients with diabetes mellitus (DM), remains unclear. Methods: In this retrospective cohort study, 843 ACS patients admitted to the 2nd Cardiology Department at Hippokration Hospital of Thessaloniki, Greece, between 2017 and 2023 were evaluated. PHR was calculated from admission complete blood counts. The primary endpoint was all-cause mortality during a median follow-up of 25 months. Multivariate logistic and Cox regression analyses, receiver operating characteristic (ROC) curves, Kaplan–Meier survival analyses, and restricted cubic spline (RCS) models were employed, with subgroup analyses by DM status. Results: Higher PHR was independently associated with increased mortality in the overall cohort (adjusted hazard ratio [aHR] 1.35, p < 0.001). This association showed stronger predictive value in DM patients, reflected in both a higher aHR (1.52 vs. 1.36 in non-DM patients, p < 0.001 and p = 0.018, respectively) and superior discriminative performance on ROC analysis (AUC 0.707 vs. 0.600 overall, p = 0.0006). Kaplan–Meier analysis confirmed poorer survival in high-PHR groups, especially in DM patients. RCS analysis revealed a J-shaped relationship, with risk increasing markedly beyond PHR values of 2.2. Conclusions: PHR is an independent predictor of long-term mortality in ACS, with greater prognostic significance in DM patients. Its simplicity, low cost, and availability from routine blood tests make it a promising tool for risk stratification in ACS.

26 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMaria Aggou
Maria Aggou
BFBarbara Fyntanidou
Barbara Fyntanidou
Marios Georgios BantidosMarios Georgios Bantidos
Marios Georgios Bantidos
APAndreas S Papazoglou
Andreas S Papazoglou
ANAthina Nasoufidou
Athina Nasoufidou
VGVasilios Grosomanidis
Vasilios Grosomanidis
Background: In-hospital cardiac arrest (IHCA) constitutes a high-impact clinical event, associated with substantial mortality, frequent neurological and functional impairment. There is a pressing need for primary IHCA studies that evaluate risk predictors, given the inherent challenges of IHCA data collection, previously unharmonized reporting frameworks, and the predominant focus of prior investigations on other domains. Among potential contributors, the “off-hours effect” has consistently been linked to poorer IHCA outcomes. Accordingly, we sought to examine whether in-hospital mortality after IHCA varies according to the time and day of occurrence within a tertiary academic center in Northern Greece. Methods: We conducted a single-center observational cohort study using a prospectively maintained in-hospital resuscitation registry at AHEPA University General Hospital, Thessaloniki. All adults with an index IHCA between 2017 and 2019 were included, and definitions followed Utstein-style recommendations. Results: Multivariable logistic regression adjusted for organizational, patient, and process-of-care factors demonstrated that afternoon/night arrests, weekend arrests, heart failure comorbidity, and need for mechanical ventilation were independent predictors of higher in-hospital mortality. Conversely, arrhythmia as the cause of IHCA and arrests occurring in the intensive care unit or operating room were associated with improved survival. Subgroup analyses confirmed consistent off-hours differences, with weekend events showing reduced 30-day and 6-month survival and worse functional status at discharge. Afternoon/night arrests were more frequent, characterized by longer response intervals and lower survival at both time points. Conclusions: Organizational factors during nights and weekends, rather than patient case mix, drive poorer IHCA outcomes, underscoring the need for targeted system-level improvements.